Hua Jian and Renhe Launch OTC Drug RWA Platform to Modernize Supply Chains
Harmony Medical (HKEX: 0370) has disclosed that its affiliate Hua Jian Medical is partnering with Renhe Worldwide, a wholly-owned arm of Renhe Pharmaceutical, to construct a brand new real-world asset (RWA) platform for over-the-counter (OTC) medication.
The enterprise is being described as the primary vertical RWA system devoted to OTC prescription drugs, with the purpose of streamlining provide chains and enhancing transparency in China’s quickly rising OTC market.
Tokenizing OTC Medicine for Safe, Actual-Time Buying and selling
The venture remains to be in improvement, however the corporations mentioned it is going to tokenize OTC pharmaceutical property, enabling safe, traceable, and real-time transactions between producers, distributors, and retailers.
By shifting drug inventories and transactions onto blockchain rails, the companions count on to chop inefficiencies, decrease prices, and enhance compliance with regulatory requirements, whereas giving market members extra confidence in product authenticity.
Associated: RWA Sector Hits Document $25B Worth, Led by Non-public Credit score and U.S. Treasuries
Renhe’s Position in Tech Infrastructure
Renhe Worldwide brings its background in digital transformation and blockchain adoption to the initiative. Its position is concentrated on growing a scalable and safe expertise infrastructure to help the platform.
Executives famous that the hassle displays Hua Jian’s broader technique to mix healthcare and expertise, notably within the distribution layer the place bottlenecks and fraud dangers typically come up.
Why China’s OTC Market Issues
China’s OTC market has been increasing in each city and rural areas as self-care and preventive drugs achieve traction. Business information cited by the businesses suggests this phase of healthcare might change into a significant development driver within the coming years.
By digitizing and tokenizing OTC drug flows, Hua Jian and Renhe purpose to speed up distribution, enhance responsiveness to demand shifts, and cut back friction in retail supply.
Business Implications
Analysts say this partnership might change into a mannequin for integrating RWAs into pharmaceutical provide chains, a sector historically gradual to adapt to digital innovation.
If profitable, the framework could affect how OTC medication are traded not solely in China but in addition throughout worldwide healthcare markets.
Associated: RWA Crypto Sector Emerges as Day’s High Performer with 6.9% Acquire
Disclaimer: The data offered on this article is for informational and academic functions solely. The article doesn’t represent monetary recommendation or recommendation of any type. Coin Version will not be liable for any losses incurred because of the utilization of content material, merchandise, or providers talked about. Readers are suggested to train warning earlier than taking any motion associated to the corporate.
